A probiotic strain called Weizmannia coagulans JA845, found in fermented sauerkraut, significantly improved blood sugar control and reduced liver fat in diabetic mice by changing gut bacteria composition and boosting GLP-1 hormone production. According to Gram Research analysis, the bacteria works through two pathways that improve how the body processes glucose and lipids, though human studies are needed before this treatment can be recommended for people.
Researchers discovered that a specific probiotic bacteria called Weizmannia coagulans JA845, found in fermented sauerkraut, may help people with type 2 diabetes manage their blood sugar and cholesterol levels. In studies with diabetic mice, this probiotic improved how the body handles glucose, reduced fat buildup in the liver, and lowered inflammation. The bacteria works by changing the gut microbiota composition and triggering special signaling pathways that boost the production of GLP-1, a hormone that helps regulate blood sugar. According to Gram Research analysis, this discovery could lead to new probiotic treatments for diabetes management.
Key Statistics
A 2026 laboratory study found that Weizmannia coagulans JA845 significantly improved glucose metabolism and enhanced insulin sensitivity in type 2 diabetic mice while reducing hepatic lipid accumulation and systemic inflammation.
Research published in Food & Function (2026) showed that W. coagulans JA845 increased specific bile acids (TβMCA and TLCA) in the gut, with TLCA activating the TGR5 signaling pathway to promote GLP-1 synthesis and secretion.
A 2026 mechanistic study demonstrated that W. coagulans JA845 reshaped gut microbiota composition by inhibiting Ligilactobacillus, a bile salt hydrolase-producing bacterium, thereby modulating bile acid metabolism in diabetic mice.
According to a 2026 research article, W. coagulans JA845 improved lipid metabolism by antagonizing the FXR signaling pathway and inhibiting FGF15 expression while simultaneously activating TGR5/CREB/PCSK1/GCG signaling for enhanced glucose control.
The Quick Take
- What they studied: Whether a specific probiotic bacteria from sauerkraut could help treat type 2 diabetes by changing how the gut bacteria work and how the body processes sugar and fat.
- Who participated: Laboratory mice with type 2 diabetes (induced by high-fat diet and a chemical), plus cell cultures grown in dishes to test specific mechanisms.
- Key finding: The probiotic strain significantly improved blood sugar control, increased insulin sensitivity, reduced fat in the liver, and lowered inflammation markers in diabetic mice.
- What it means for you: This research suggests a potential new probiotic treatment for type 2 diabetes, though human studies are needed before recommendations can be made. It’s too early to use this specific strain as a treatment, but it shows promise for future diabetes management options.
The Research Details
Researchers used two main approaches to test this probiotic. First, they created mice with type 2 diabetes by feeding them a high-fat diet and giving them a chemical that damages the pancreas. They then gave some mice the probiotic bacteria and measured changes in blood sugar, insulin levels, liver fat, and inflammation. Second, they grew special intestinal cells in dishes and exposed them to the probiotic to understand exactly how it works at the cellular level.
The team analyzed the gut bacteria in the mice using genetic sequencing to see which bacteria increased or decreased after probiotic treatment. They also measured specific bile acids (chemicals made by the liver that help digest fat) and tracked how different signaling pathways in cells were activated or deactivated.
This combination of whole-animal studies and detailed cellular experiments allowed researchers to both see that the probiotic worked and understand the biological mechanisms behind that improvement.
Using both animal models and cell cultures is important because it shows the probiotic works at multiple levels—improving the whole organism’s health while also demonstrating specific molecular pathways involved. This dual approach makes the findings more convincing and helps explain exactly how the bacteria helps the body.
This is a laboratory-based research study, which means it demonstrates proof-of-concept but hasn’t been tested in humans yet. The use of genetic sequencing and multiple measurement techniques strengthens the findings. However, mouse studies don’t always translate directly to humans, so human clinical trials would be needed to confirm these results are safe and effective for people with diabetes.
What the Results Show
The probiotic strain W. coagulans JA845 produced significant improvements in diabetic mice across multiple measures. Blood sugar control improved, meaning the mice’s bodies handled glucose better. Insulin sensitivity increased, indicating the mice’s cells responded better to insulin signals. The amount of fat stored in the liver decreased substantially, which is important because fatty liver disease often accompanies type 2 diabetes.
Systemic inflammation—the body-wide inflammatory response that damages health—was significantly reduced. These improvements occurred because the probiotic changed which bacteria lived in the gut. Specifically, it reduced a bacterium called Ligilactobacillus that produces an enzyme called bile salt hydrolase.
The mechanism works through two main pathways. First, the probiotic increases certain bile acids (TβMCA and TLCA) that trigger specific cellular receptors. TβMCA blocks a pathway called FXR signaling, which helps improve how the body processes fats. TLCA activates a different pathway called TGR5 signaling, which boosts production of GLP-1, a hormone that helps regulate blood sugar and insulin release.
The study revealed that the probiotic’s effects depend on reshaping the gut microbiota—simply having the bacteria present wasn’t enough; it had to change the overall bacterial community. The specific bile acids produced were crucial; the probiotic worked by altering which bile acids accumulated in the gut rather than by producing them directly. The activation of GLP-1 production was particularly important, as GLP-1 is a hormone that naturally helps control blood sugar and is the target of several diabetes medications.
This research builds on existing knowledge that probiotics can influence metabolism through the gut microbiota and bile acid pathways. However, this appears to be the first study to specifically identify how W. coagulans JA845 modulates both the FXR and TGR5 signaling pathways simultaneously to improve glucose and lipid metabolism. Previous research suggested these pathways were important; this study demonstrates a specific probiotic mechanism that activates both.
This study was conducted entirely in laboratory settings—mice and cell cultures—not in humans. Mouse metabolism differs from human metabolism in important ways, so results may not translate directly. The study doesn’t specify exact sample sizes for the mouse experiments. No information is provided about whether the probiotic would survive the human digestive system or colonize the human gut. Long-term safety and effectiveness in humans remain unknown. The study also doesn’t compare this probiotic to existing diabetes treatments or other probiotics.
The Bottom Line
This research is preliminary and laboratory-based only. Do not use this specific probiotic strain as a diabetes treatment yet—human clinical trials are necessary first. However, the findings suggest that targeted probiotics may eventually become a useful tool for diabetes management. People with type 2 diabetes should continue following their doctor’s current treatment plans while this research progresses toward human testing. General consumption of fermented foods like sauerkraut (which contains various probiotics) remains a reasonable dietary choice, though this specific strain hasn’t been tested in humans.
People with type 2 diabetes or those at risk for developing it should follow this research as it progresses. Healthcare providers managing diabetes should be aware of emerging probiotic research. Researchers studying probiotics and metabolic disease should note this mechanism. People should NOT self-treat with this specific strain based on this study. General audiences interested in gut health and fermented foods may find this research interesting but shouldn’t expect immediate practical applications.
This research is in early stages. Human clinical trials would likely take 2-5 years to complete if they begin soon. Even after successful human trials, regulatory approval and commercial availability could take several additional years. Realistic timeline for this specific probiotic becoming available as a treatment: 5-10 years at minimum.
Frequently Asked Questions
Can I use this probiotic strain to treat my type 2 diabetes?
Not yet. This specific probiotic has only been tested in mice and cell cultures, not in humans. Human clinical trials are necessary before it can be recommended as a diabetes treatment. Continue following your doctor’s current diabetes management plan.
Does eating sauerkraut give me the same benefits as this probiotic strain?
Possibly, but not necessarily. While this probiotic strain was isolated from fermented sauerkraut, commercial sauerkraut may contain different bacterial strains and in different amounts. Eating fermented foods is generally healthy, but this specific strain’s effects haven’t been tested in humans.
How does this probiotic help with blood sugar control?
The bacteria changes which microbes live in your gut, which alters bile acid production. These bile acids activate signaling pathways that boost GLP-1 hormone production—the same hormone targeted by some diabetes medications—improving how your body handles glucose.
When will this probiotic be available as a treatment?
Human clinical trials would need to occur first, which typically takes 2-5 years. Even after successful trials, regulatory approval and commercial availability could take several more years. Realistic timeline: 5-10 years minimum before widespread availability.
Is this probiotic safe for people with diabetes?
Safety hasn’t been tested in humans yet. While the mouse studies showed benefits without apparent harm, human safety testing is required before recommendations can be made. People with diabetes should consult their doctor before trying any new supplements.
Want to Apply This Research?
- Users could track daily fermented food consumption (servings of sauerkraut, kimchi, yogurt, kefir) and correlate with blood sugar readings if they have a glucose monitor, noting any patterns over 4-week periods.
- Encourage users to gradually increase fermented food intake to 1-2 servings daily while maintaining their current diabetes management plan, logging which fermented foods they consume and any digestive changes.
- Set weekly reminders to log fermented food intake and monthly check-ins with healthcare providers to ensure blood sugar management remains stable while dietary changes are made. Track any changes in energy levels, digestion, or blood sugar patterns.
This research is preliminary laboratory-based science conducted in mice and cell cultures, not humans. These findings do not constitute medical advice or a recommendation to use this probiotic strain for diabetes treatment. People with type 2 diabetes should continue following their healthcare provider’s treatment recommendations and should not self-treat based on this research. Human clinical trials are necessary before this probiotic can be considered safe or effective for human use. Anyone considering dietary changes or supplements should consult with their healthcare provider, especially if they have diabetes or take diabetes medications. This article is for educational purposes only and should not replace professional medical guidance.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.